MCID: PNL012
MIFTS: 58

Penile Cancer malady

Categories: Cancer diseases, Reproductive diseases, Rare diseases

Aliases & Classifications for Penile Cancer

Aliases & Descriptions for Penile Cancer:

Name: Penile Cancer 12 14
Penis Carcinoma 12 14 69
Penile Neoplasms 42 69
Penile Neoplasm 12 14
Malignant Neoplasm of Body of Penis 12
Malignant Neoplasm of Penis 69
Malignant Penile Tumor 12
Carcinoma of Penis 12
Neoplasm of Penis 12
Penile Carcinoma 12
Penile Tumor 12
Penile Ca 12
Ca Penis 12

Classifications:



Summaries for Penile Cancer

Disease Ontology : 12 A penile cancer that is located in the skin or tissues of the penis.

MalaCards based summary : Penile Cancer, also known as penis carcinoma, is related to penis carcinoma in situ and penile cancer, adult. An important gene associated with Penile Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Udenafil and Leuprolide have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and prostate, and related phenotypes are Decreased viability and homeostasis/metabolism

Wikipedia : 71 Penile cancer is a malignant growth found on the skin or in the tissues of the penis. Around 95% of... more...

Related Diseases for Penile Cancer

Diseases in the Penile Cancer family:

Penile Cancer, Adult

Diseases related to Penile Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
id Related Disease Score Top Affiliating Genes
1 penis carcinoma in situ 11.9
2 penile cancer, adult 11.9
3 penile cancer, childhood 11.9
4 penis squamous cell carcinoma 11.2
5 penis basaloid carcinoma 10.9
6 penis papillary carcinoma 10.9
7 penis verrucous carcinoma 10.9
8 wolffian adnexal neoplasm 10.3 EGFR TP53
9 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
10 pericardium leiomyoma 10.3 CDKN2A TP53
11 immunodeficiency due to a classical component pathway complement deficiency 10.3 CDKN2A EGFR
12 verruciform xanthoma of skin 10.3 PIK3CA TP53
13 uterine corpus choriocarcinoma 10.2 PIK3CA PTEN
14 lacrimal gland squamous cell carcinoma 10.2 CDKN2A TP53
15 malignant skin fibrous histiocytoma 10.2 HRAS KRAS
16 agenesis and aplasia of uterine body 10.2 EGFR KRAS
17 thymus squamous cell carcinoma 10.2 CDKN2A EGFR TP53
18 reticulosarcoma 10.2 SMUG1 TP53
19 spastic paraplegia 1 10.2 EGFR PIK3CA TP53
20 urethral villous adenoma 10.2 CDKN2A EGFR
21 estrogen-receptor positive breast cancer 10.2 CDKN2A EGFR TP53
22 pityriasis rosea 10.2 CDKN2A EGFR TP53
23 reactive arthritis 10.2 EGFR PIK3CA TP53
24 paternal uniparental disomy of chromosome 1 10.2 EGFR TP53
25 pyomyositis 10.2 CDKN2A EGFR TP53
26 childhood-onset cerebral x-linked adrenoleukodystrophy 10.2 CDKN2A EGFR TP53
27 progesterone-receptor positive breast cancer 10.2 CDKN2A EGFR TP53
28 spondylarthropathy 10.2 CDKN2A HRAS TP53
29 mitochondrial neurogastrointestinal encephalopathy disease 10.2 KRAS TP53
30 chronic venous insufficiency 10.2 HRAS KRAS
31 childhood embryonal testis carcinoma 10.2 EGFR PTEN TP53
32 gallbladder pleomorphic giant cell adenocarcinoma 10.2 CDKN2A HRAS TP53
33 ornithinemia 10.2 CDKN2A EGFR TP53
34 stenosis of lacrimal punctum 10.2 EGFR HRAS PIK3CA
35 adult epithelioid sarcoma 10.2 CDKN2A HRAS TP53
36 occlusion precerebral artery 10.2 CDKN2A EGFR TP53
37 glioma susceptibility 2 10.2 EGFR PIK3CA PTEN
38 infantile thalamic degeneration 10.2 KRAS TP53
39 erythrocyte lactate transporter defect 10.2 HRAS KRAS
40 urethral cancer 10.2 KRAS PIK3CA
41 exudative glomerulonephritis 10.2 EGFR KRAS TP53
42 urethral verrucous carcinoma 10.2 CDKN2A PTEN TP53
43 early myoclonic encephalopathy 10.2 EGFR PTEN TP53
44 acute hemorrhagic encephalitis 10.2 HRAS SMUG1
45 breast leiomyoma 10.1 CDKN2A PIK3CA TP53
46 alpha chain disease 10.1 CDKN2A HRAS TP53
47 sengers syndrome 10.1 CDKN2A EGFR PTEN
48 immature teratoma of ovary 10.1 HRAS PTEN
49 intermediate malignant teratoma 10.1 CDKN2A EGFR KRAS
50 benign ependymoma 10.1 EGFR KRAS TP53

Graphical network of the top 20 diseases related to Penile Cancer:



Diseases related to Penile Cancer

Symptoms & Phenotypes for Penile Cancer

GenomeRNAi Phenotypes related to Penile Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.22 KRAS PIK3CA EGFR HRAS
2 Decreased viability GR00106-A-0 10.22 KRAS
3 Decreased viability GR00221-A-1 10.22 KRAS PIK3CA CDKN2A EGFR HRAS
4 Decreased viability GR00221-A-2 10.22 KRAS PIK3CA HRAS
5 Decreased viability GR00221-A-3 10.22 CDKN2A HRAS
6 Decreased viability GR00221-A-4 10.22 PIK3CA CDKN2A EGFR
7 Decreased viability GR00301-A 10.22 KRAS
8 Decreased viability GR00381-A-1 10.22 KRAS
9 Decreased cell migration GR00055-A-1 9.46 EGFR HRAS KRAS PIK3CA
10 Increased cell migration GR00055-A-3 8.92 EGFR HRAS KRAS PIK3CA

MGI Mouse Phenotypes related to Penile Cancer:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 PIK3CA PTEN SCN10A SMUG1 TP53 APP
2 behavior/neurological MP:0005386 10.17 APP CDKN2A HRAS KRAS PIK3CA PTEN
3 cardiovascular system MP:0005385 10.16 CDKN2A EGFR HRAS KRAS PIK3CA PTEN
4 cellular MP:0005384 10.15 APP CDKN2A EGFR KRAS PIK3CA PTEN
5 integument MP:0010771 10.15 APP CDKN2A EGFR HRAS KRAS PIK3CA
6 mortality/aging MP:0010768 10.13 CDKN2A EGFR HRAS APP KRAS PIK3CA
7 endocrine/exocrine gland MP:0005379 10.07 KRAS PIK3CA PTEN TP53 CDKN2A EGFR
8 nervous system MP:0003631 10.06 APP CDKN2A EGFR HRAS KRAS PIK3CA
9 neoplasm MP:0002006 10.03 CDKN2A EGFR HRAS KRAS PIK3CA PTEN
10 embryo MP:0005380 10.01 CDKN2A EGFR KRAS PIK3CA PTEN TP53
11 muscle MP:0005369 10 APP CDKN2A EGFR KRAS PIK3CA PTEN
12 no phenotypic analysis MP:0003012 9.97 APP CDKN2A EGFR HRAS KRAS PIK3CA
13 reproductive system MP:0005389 9.8 APP CDKN2A EGFR KRAS PIK3CA PTEN
14 pigmentation MP:0001186 9.72 CDKN2A EGFR KRAS PTEN TP53
15 respiratory system MP:0005388 9.7 CDKN2A EGFR HRAS KRAS PTEN SCN10A
16 skeleton MP:0005390 9.5 CDKN2A EGFR HRAS KRAS PIK3CA PTEN
17 vision/eye MP:0005391 9.1 CDKN2A EGFR KRAS PIK3CA PTEN TP53

Drugs & Therapeutics for Penile Cancer

Drugs for Penile Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
2
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
3
Tadalafil Approved, Investigational Phase 4,Phase 3 171596-29-5 110635
4 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
5 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
6 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
7 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Early Phase 1
8 Fertility Agents Phase 4
9 Vasodilator Agents Phase 4,Phase 3,Early Phase 1
10 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2
11 Coagulants Phase 4
12 Hemostatics Phase 4
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Methyltestosterone Approved Phase 3,Early Phase 1 58-18-4 6010
15
Testosterone Approved, Investigational Phase 3,Early Phase 1 58-22-0 6013
16
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
17
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
18
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
19
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
20
Clonidine Approved Phase 3 4205-90-7 2803
21
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
22
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
23
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
24
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
25
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
26 tannic acid Approved, Nutraceutical Phase 3
27 Liver Extracts Phase 3,Phase 2,Phase 1
28 HIV Protease Inhibitors Phase 3,Phase 2
29
protease inhibitors Phase 3,Phase 2
30 Adjuvants, Anesthesia Phase 3
31 Analgesics Phase 3,Phase 2
32 Analgesics, Opioid Phase 3
33 Anesthetics Phase 3,Phase 1,Phase 2
34 Anesthetics, General Phase 3
35 Anesthetics, Intravenous Phase 3
36 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
37 Narcotics Phase 3
38 pancreatic polypeptide Phase 3
39 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
40 Anticoagulants Phase 3
41 Calcium, Dietary Phase 3
42 Chelating Agents Phase 3
43 Hormone Antagonists Phase 3,Early Phase 1
44 Hormones Phase 3,Early Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Early Phase 1
46 Sildenafil Citrate Phase 3,Phase 2,Early Phase 1 171599-83-0
47 Testosterone 17 beta-cypionate Phase 3,Early Phase 1
48
Testosterone enanthate Phase 3,Early Phase 1 315-37-7 9416
49 Testosterone undecanoate Phase 3,Early Phase 1
50 Neurotransmitter Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 100)
id Name Status NCT ID Phase
1 The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer Completed NCT01421940 Phase 4
2 Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer Completed NCT01511874 Phase 4
3 A Study of Tadalafil After Radical Prostatectomy Completed NCT01026818 Phase 4
4 Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer. Recruiting NCT02001857 Phase 4
5 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Recruiting NCT01824537 Phase 4
6 Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer Unknown status NCT00154752 Phase 3
7 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3
8 Mechanical Nerve Stimulation in the Treatment of Post Prostatectomy Incontinence Unknown status NCT01540656 Phase 3
9 Evaluating the Effect of the VCD on Erectile Function and Penile Length Post RRP Completed NCT00177125 Phase 3
10 Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial Completed NCT00247312 Phase 3
11 An Investigational Study of Gardasil™ (qHPV, V501) Vaccine in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) Completed NCT00090285 Phase 3
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
13 Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer Completed NCT00142506 Phase 3
14 Pelvic Floor Muscle Training and Biofeedback or Standard Therapy in Men Who Have Undergone Radical Prostatectomy or Transurethral Resection of the Prostate Completed NCT00632138 Phase 3
15 Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy Completed NCT00895011 Phase 3
16 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
17 Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts Completed NCT00449982 Phase 3
18 Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis Recruiting NCT02740127 Phase 3
19 Efficacy and Tolerability Study of V501 in Japanese Males (V501-122) Active, not recruiting NCT01862874 Phase 3
20 International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) Not yet recruiting NCT02305654 Phase 3
21 Can Tadalafil Maintain Erectile Function In Patients Treated With Radiotherapy For Prostate Cancer? Terminated NCT00215631 Phase 3
22 Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET] Unknown status NCT02104063 Phase 2
23 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
24 High-Intensity Focused Ultrasound in Treating Patients With Localized Prostate Cancer Unknown status NCT01194648 Phase 2
25 A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis Completed NCT03114254 Phase 2
26 Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer Completed NCT00066391 Phase 2
27 Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis Completed NCT00512096 Phase 2
28 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2
29 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 2
30 Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer Completed NCT00002506 Phase 2
31 Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma Completed NCT00210041 Phase 2
32 Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer Completed NCT00039624 Phase 2
33 Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction Completed NCT01089387 Phase 1, Phase 2
34 Immune Therapy of HPV-induced Cancers Completed NCT01462838 Phase 1, Phase 2
35 Oral Rigosertib for Squamous Cell Carcinoma Completed NCT01807546 Phase 2
36 Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis Recruiting NCT01728233 Phase 2
37 Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Recruiting NCT02837042 Phase 2
38 Role of Low-intensity Shock Wave Therapy in Penile Rehabilitation Post Nerve Sparing Radical Cysto-prostatectomy Recruiting NCT02422277 Phase 2
39 Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma Recruiting NCT02541903 Phase 2
40 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2
41 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
42 Stem Cell Therapy Combined With NeuroRegen Scaffold™ in Patients With Erectile Dysfunction After Rectal Cancer Surgery Recruiting NCT02648386 Phase 1, Phase 2
43 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
44 A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP) Active, not recruiting NCT02057913 Phase 2
45 Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis Active, not recruiting NCT02817958 Phase 2
46 Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males Active, not recruiting NCT01209325 Phase 2
47 Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types Not yet recruiting NCT03012581 Phase 2
48 S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) Terminated NCT00058448 Phase 2
49 Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG) Terminated NCT02279576 Phase 2
50 Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) Withdrawn NCT02014831 Phase 2

Search NIH Clinical Center for Penile Cancer

Cochrane evidence based reviews: penile neoplasms

Genetic Tests for Penile Cancer

Anatomical Context for Penile Cancer

MalaCards organs/tissues related to Penile Cancer:

39
Skin, Lymph Node, Prostate, Neutrophil, Kidney, Breast, Testis

The Foundational Model of Anatomy Ontology organs/tissues related to Penile Cancer:

18
The Skin Or Tissues Of The Penis

Publications for Penile Cancer

Articles related to Penile Cancer:

(show top 50) (show all 381)
id Title Authors Year
1
Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study. ( 27771796 )
2017
2
The Patterns of Practice and Outcomes of Penile Cancer in Ontario. ( 28057403 )
2017
3
A Contemporary Review of HPV and Penile Cancer. ( 26984219 )
2016
4
Expression of Programmed Death Ligand 1 in Penile Cancer Is of Prognostic Value and Associated with HPV Status. ( 27697578 )
2016
5
Re: EAU Guidelines on Penile Cancer: 2014 Update. ( 27186734 )
2016
6
Dr. Arthur L. Burnett: surgical treatment for penile cancer. ( 27785442 )
2016
7
Tumor histologic grade is the most important prognostic factor in patients with penile cancer and clinically negative lymph nodes not submitted to regional lymphadenectomy. ( 27813383 )
2016
8
A study on the value of computer-assisted assessment for SPECT/CT-scans in sentinel lymph node diagnostics of penile cancer as well as clinical reliability and morbidity of this procedure. ( 27604900 )
2016
9
HPV and Penile Cancer: Perspectives on the Future Management of HPV-Positive Disease. ( 26984224 )
2016
10
Establishment and characterization of a penile cancer cell line, penl1, with a deleterious TP53 mutation as a paradigm of HPVnegative penile carcinogenesis. ( 27351128 )
2016
11
Prospective study comparing Videoendoscopic radical Inguinal Lymph node dissection (VEILND) with Open radical inguinal lymphnode dissection (OILND) for penile cancer over an 8 year period. ( 27628265 )
2016
12
Penile Cancer: The Importance to predict lymph node metastasis. ( 27813379 )
2016
13
Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in penile cancer. ( 27203206 )
2016
14
Increased neutrophil-to-lymphocyte ratio is associated with disease-specific mortality in patients with penile cancer. ( 27386948 )
2016
15
Obesity is associated with increased risk of invasive penile cancer. ( 27411982 )
2016
16
Advantages by using the intradermal microbubbles for sentinel lymph node detection in penile cancer. ( 27824971 )
2016
17
Organ-sparing treatment of penile cancer with interstitial pulsed-dose-rate brachytherapy. ( 27276876 )
2016
18
Radiotherapy approaches for locally advanced penile cancer: neoadjuvant and adjuvant. ( 27584027 )
2016
19
Penile cancer metastasizing to the breast: a case report. ( 26961850 )
2016
20
Penile preserving and reconstructive surgery in the management of penile cancer. ( 27001013 )
2016
21
Radiocolloid-based dynamic sentinel lymph node biopsy in penile cancer with clinically negative inguinal lymph node: an updated systematic review and meta-analysis. ( 27577753 )
2016
22
A prospective study of total glans resurfacing in localised penile cancer to maximise oncological and functional outcomes within a tertiary referral network. ( 28027867 )
2016
23
Glansectomy and Split-thickness Skin Graft for Penile Cancer. ( 27746062 )
2016
24
Centralization of Penile Cancer Management in the United States: A Combined Analysis of the American Board of Urology and National Cancer Data Base. ( 26827845 )
2016
25
Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients). ( 27464910 )
2016
26
Emerging Systemic Therapies for the Management of Penile Cancer. ( 27717434 )
2016
27
15 Years of penile cancer management in the United States: An analysis of the use of partial penectomy for localized disease and chemotherapy in the metastatic setting. ( 27495001 )
2016
28
One-day protocol appears safe for managing the primary tumour and regional nodes in penile cancer. ( 27173997 )
2016
29
10-Year experience regarding the reliability and morbidity of radio guided lymph node biopsy in penile cancer patients and the associated radiation exposure of medical staff in this procedure. ( 27485215 )
2016
30
PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors? ( 27436847 )
2016
31
Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer. ( 26935231 )
2016
32
Multimodal Therapy in the Management of Advanced Penile Cancer. ( 27717433 )
2016
33
Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study. ( 28066240 )
2016
34
Re: Treatment for Metastatic Penile Cancer after First-Line Chemotherapy Failure: Analysis of Response and Survival Outcomes. ( 26887712 )
2016
35
Incremental value of MRI for preoperative penile cancer staging. ( 27402024 )
2016
36
Beyond penile cancer, is there a role for sentinel node biopsy in urological malignancies? ( 27738628 )
2016
37
Preoperative peripheral plasma fibrinogen level is an independent prognostic marker in penile cancer. ( 27738342 )
2016
38
Management of Penile Cancer. ( 26802797 )
2016
39
The Danish National Penile Cancer Quality database. ( 27822104 )
2016
40
Penile cancer: Prognostic value of PD-L1 status. ( 27754476 )
2016
41
Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression. ( 26905033 )
2016
42
Penile cancer: Welcome changes in disease management and remaining challenges. ( 27797359 )
2016
43
Disparities in Penile Cancer. ( 27842330 )
2016
44
Racial Disparities Differ for African Americans and Hispanics in the Diagnosis and Treatment of Penile Cancer. ( 27402373 )
2016
45
Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies. ( 27314890 )
2016
46
Penile cancer: Ongoing search for molecular prognostic markers. ( 26954331 )
2016
47
Socioeconomic factors and penile cancer risk and mortality; a population-based study. ( 27373878 )
2016
48
Volume-outcome relationship in penile cancer treatment: a population based patterns of care and outcomes study from Australia. ( 27792850 )
2016
49
The evolving landscape in advanced penile cancer. ( 28031884 )
2015
50
Neoadjuvant chemotherapy with cetuximab for locally advanced penile cancer. ( 26881664 )
2015

Variations for Penile Cancer

Cosmic variations for Penile Cancer:

9 (show all 19)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM12475 CDKN2A skin,penis,carcinoma,squamous cell carcinoma c.238C>T p.R80* 15
2 COSM10656 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.742C>T p.R248W 7
3 COSM11491 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.743G>C p.R248P 7
4 COSM10660 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.818G>A p.R273H 7
5 COSM45765 TP53 skin,leg,carcinoma,squamous cell carcinoma c.987C>A p.T329T 7
6 COSM45114 TP53 skin,leg,carcinoma,squamous cell carcinoma c.702C>A p.Y234* 7
7 COSM10863 TP53 skin,leg,carcinoma,squamous cell carcinoma c.833C>T p.P278L 7
8 COSM214151 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.585G>A p.W195* 7
9 COSM1731707 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.1789C>T p.Q597* 7
10 COSM1735721 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.297G>A p.W99* 7
11 COSM1735722 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.298G>A p.G100R 7
12 COSM5316 PTEN skin,NS,carcinoma,Merkel cell carcinoma c.439A>T p.K147* 7
13 COSM249774 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.56G>A p.R19K 7
14 COSM760 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1624G>A p.E542K 7
15 COSM27133 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1633G>C p.E545Q 7
16 COSM766 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1636C>A p.Q546K 7
17 COSM776 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.3140A>T p.H1047L 7
18 COSM763 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1633G>A p.E545K 7
19 COSM498 HRAS skin,leg,carcinoma,squamous cell carcinoma c.182A>T p.Q61L 7

Expression for Penile Cancer

Search GEO for disease gene expression data for Penile Cancer.

Pathways for Penile Cancer

Pathways related to Penile Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 110)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 APP EGFR HRAS IFNA2 KRAS PIK3CA
2
Show member pathways
13.82 APP CDKN2A EGFR HRAS IFNA2 KRAS
3
Show member pathways
13.5 EGFR HRAS IFNA2 KRAS PIK3CA TP53
4
Show member pathways
13.42 EGFR HRAS KRAS PIK3CA PTEN TP53
5
Show member pathways
13.34 EGFR HRAS IFNA2 KRAS PIK3CA TP53
6
Show member pathways
13.3 APP HRAS IFNA2 KRAS PIK3CA TP53
7
Show member pathways
13.04 EGFR HRAS KRAS PTEN TP53
8
Show member pathways
12.97 CDKN2A EGFR HRAS KRAS PIK3CA PTEN
9
Show member pathways
12.91 EGFR HRAS KRAS PIK3CA PTEN
10
Show member pathways
12.9 EGFR HRAS KRAS PIK3CA TP53
11
Show member pathways
12.9 EGFR HRAS KRAS PIK3CA PTEN
12
Show member pathways
12.9 HRAS IFNA2 KRAS PIK3CA PTEN TP53
13
Show member pathways
12.89 CDKN2A EGFR HRAS KRAS SCN10A
14
Show member pathways
12.87 EGFR HRAS KRAS PIK3CA PTEN
15
Show member pathways
12.82 CDKN2A HRAS KRAS PIK3CA TP53
16
Show member pathways
12.8 EGFR HRAS KRAS PIK3CA PTEN
17
Show member pathways
12.8 HRAS KRAS PIK3CA PTEN TP53
18
Show member pathways
12.77 HRAS KRAS PIK3CA PTEN
19
Show member pathways
12.71 EGFR HRAS KRAS PIK3CA
20 12.7 EGFR HRAS KRAS TP53
21
Show member pathways
12.7 EGFR HRAS KRAS PIK3CA PTEN TP53
22
Show member pathways
12.66 EGFR HRAS KRAS TP53
23 12.62 EGFR HRAS KRAS PIK3CA
24
Show member pathways
12.6 EGFR HRAS KRAS PIK3CA TP53
25
Show member pathways
12.59 HRAS KRAS PIK3CA PTEN
26 12.57 CDKN2A EGFR HRAS KRAS PIK3CA PTEN
27
Show member pathways
12.56 EGFR HRAS KRAS PIK3CA TP53
28
Show member pathways
12.53 HRAS IFNA2 KRAS PIK3CA
29
Show member pathways
12.5 HRAS KRAS PIK3CA PTEN
30 12.48 EGFR HRAS IFNA2 KRAS PIK3CA PTEN
31
Show member pathways
12.47 EGFR HRAS KRAS PIK3CA PTEN TP53
32
Show member pathways
12.45 EGFR HRAS KRAS PIK3CA TP53
33 12.43 CDKN2A HRAS KRAS PIK3CA TP53
34
Show member pathways
12.42 EGFR HRAS KRAS PIK3CA
35
Show member pathways
12.41 HRAS PIK3CA PTEN TP53
36
Show member pathways
12.4 HRAS KRAS PIK3CA PTEN
37
Show member pathways
12.35 HRAS KRAS PIK3CA PTEN
38 12.34 CDKN2A EGFR HRAS KRAS PIK3CA PTEN
39
Show member pathways
12.33 EGFR HRAS KRAS PIK3CA TP53
40
Show member pathways
12.31 EGFR HRAS KRAS PIK3CA
41 12.31 EGFR HRAS KRAS PIK3CA TP53
42
Show member pathways
12.31 EGFR HRAS KRAS PIK3CA PTEN TP53
43 12.3 CDKN2A HRAS KRAS PIK3CA TP53
44
Show member pathways
12.26 EGFR HRAS KRAS PTEN
45 12.22 EGFR HRAS KRAS PTEN
46
Show member pathways
12.21 EGFR KRAS PTEN TP53
47 12.2 HRAS KRAS PIK3CA
48
Show member pathways
12.2 HRAS IFNA2 PIK3CA
49
Show member pathways
12.2 HRAS KRAS PIK3CA TP53
50
Show member pathways
12.18 HRAS KRAS PIK3CA

GO Terms for Penile Cancer

Biological processes related to Penile Cancer according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.92 EGFR HRAS KRAS PTEN
2 cell proliferation GO:0008283 9.87 EGFR HRAS PTEN TP53
3 negative regulation of cell proliferation GO:0008285 9.83 APP CDKN2A HRAS PTEN TP53
4 apoptotic process GO:0006915 9.8 APP CDKN2A HRAS IFNA2 PTEN TP53
5 T cell receptor signaling pathway GO:0050852 9.77 HRAS PIK3CA PTEN
6 cell cycle arrest GO:0007050 9.77 CDKN2A HRAS TP53
7 positive regulation of gene expression GO:0010628 9.77 APP HRAS KRAS PTEN TP53
8 negative regulation of neuron apoptotic process GO:0043524 9.75 HRAS KRAS PIK3CA
9 positive regulation of protein phosphorylation GO:0001934 9.71 APP EGFR HRAS KRAS
10 liver development GO:0001889 9.7 EGFR KRAS PIK3CA
11 regulation of protein stability GO:0031647 9.67 CDKN2A KRAS PTEN
12 positive regulation of MAP kinase activity GO:0043406 9.65 EGFR HRAS KRAS
13 learning or memory GO:0007611 9.63 APP EGFR PTEN
14 cellular response to gamma radiation GO:0071480 9.62 HRAS TP53
15 cellular senescence GO:0090398 9.61 CDKN2A HRAS
16 regulation of long-term neuronal synaptic plasticity GO:0048169 9.58 HRAS KRAS
17 regulation of synaptic transmission, GABAergic GO:0032228 9.56 KRAS PTEN
18 phosphatidylinositol-mediated signaling GO:0048015 9.56 EGFR PIK3CA PTEN TP53
19 replicative senescence GO:0090399 9.55 CDKN2A TP53
20 response to isolation stress GO:0035900 9.54 HRAS KRAS
21 positive regulation of cellular senescence GO:2000774 9.51 CDKN2A KRAS
22 Ras protein signal transduction GO:0007265 9.46 CDKN2A HRAS KRAS TP53
23 epidermal growth factor receptor signaling pathway GO:0007173 9.26 EGFR HRAS KRAS PIK3CA
24 ERBB2 signaling pathway GO:0038128 8.92 EGFR HRAS KRAS PIK3CA
25 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.01 APP CDKN2A EGFR HRAS TP53

Molecular functions related to Penile Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.26 CDKN2A EGFR PTEN TP53
2 enzyme binding GO:0019899 8.92 APP EGFR PTEN TP53

Sources for Penile Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....